Table 2. Clinicopathological characteristics of NSCLC patients and expression of BZRAP1-AS1 in tumor tissues and normal tissues.

Variables	No. of Cases	BZRAP1-AS1 expression (Median, 25–75 Percentile)
		Tumor tissues	P value	Normal tissues	P value
Smoking history			0.535		0.604
No	22	0.751, 0.086–4.913		1.380, 0.165–13.416
Yes	41	0.235, 0.025–2.695		0.737, 0.061–14.324
Histologic type			0.103		0.326
LUAD	35	1.020, 0.123–4.581		1.413, 0.167–13.380
LUSC	28	0.126, 0.017–2.486		0.556, 0.059–11.459
T stage			0.040		0.071
T1	29	1.528, 0.117–12.300		1.763, 0.264–17.199
T2–T4	34	0.169, 0.021–1.594		0.364, 0.066–6.737
Lymphatic metastasis			0.032		0.018
N0	40	1.354, 0.094–5.843		2.346, 0.216–14.076
N1 + N2	23	0.180, 0.001–1.020		0.359, 0.038–1.413
Pleura invasion			0.333		0.956
Negative	35	0.185, 0.046–1.564		0.737, 0.135–13.525
Positive	28	1.408, 0.048–5.379		1.145, 0.053–12.290
Vessel carcinoma embolus			0.596		0.845
Negative	37	0.235, 0.037–3.696		0.905, 0.120–10.858
Positive	26	0.630, 0.082–6.116		1.133, 0.077–14.382

Notes.

Bold indicates that the difference is statistically significant (P < 0.05).